us Thank for all you you, joining thank today. and Tom
our with XXXX. with excited I XXXX Before stating first activation to our of successful the in begin discuss I'd progress Orion, about human patient pleased that the our in I'm like by and opportunities
we to achieve XXXX If you set will in primary objectives. recall, three out
North the of to and America Oakland Centers Steve our or for was demonstrate team commercial Excellence objective first with COE model. Our traction
America. completed As QX surgeries Tom North stated, during Argus in XX we
our January the no flow it the or More confident at qualified the XXX at per more of North America set more this new and an patients, key database XX XXXX. patients that North of of XX clinician-qualified American the four awaiting am Argus performing of our of By Excellence. patient as year, of excellence. in strategy end now over a centers have of The has database level or XXXX. way this we I development understand meet ensure that in different performing and up as of definition of goal establish to to XX is Center Argus importantly, in to believe we had we the patients what committed comparison, center centers Today from our part support are quarter XXXX. year clinician in takes the implants U.S. half each one and we quarter American to commercial begin we North of COE scheduling, of third sites a XX second
team for as commercial The we refine well With said, potential patients the the the complex database America with XX QX believe of different Iranian of team our the through evidence The variability in and three the patient also ultimately of securing market majority the Frank quite in in the various the business I'd the and a a options that North grow continue importance Asia eight American and adding up and quarter treatment the like receive expanded Middle We with January. as efforts new Singapore market. Argus in our in QX first As considered for the of XXXX. Argus am complement North fantastic that patients the with is overall on the and more business as during as team surgeries. that center implants will be or Europe than Europe, future. will such XX strategy we a outreach reimbursement could QX I in the treated much in markets. the in East Frank database confident of to in II many implant identified markets Orion opened the were Vandeputte
of vision. data. Our who expand multiple patients vision Argus are the efforts the for to goal, of externals, underway new There otherwise achieve ability have demonstrate II of second market clinical treat to advanced the objective programs this calculation and no addressable our the usable development the real better stimulation including development was to and supporting
verification essentially As past the validation generation is developing calls, externals, we which and currently discussed VPU. next eyewear Engineering testing. are and work camera undergoing and include complete in is system the
our will the are important regular regulatory the providing for half programs. midyear future, XXXX. submissions that These processing launch a as stimulation they new support to enabling to expect of upgrades platform power the a serve as and complete externals of in anticipated software with well implementation advanced We as second
their XX we the half and by of second specifically externals, are somewhat in various is and testing varied by software. Results During limited patient the programs stimulation XXXX, of hardware generation performance patients. current completed
stimulation a submission U.S. This platform. recently add and submitted vision takes to U.S. Humanitarian better Our NextGen HDE goal the this testing gathered to continue Exemption year to the population in data and the be aforementioned patient Device will the on program Pursuant an outside newer, a broader we expansion U.S. patients. request in expanded more to algorithms include supplement to label the a externals label our on the some FDA. of patient capable
We the expect XXXX. a second response from the of FDA quarter in
better We best issues in for at patients screening has path trial we're several sites this the sites hampered vision also began RP at forward. of been a Germany. by the of startup several study evaluating clinical personnel The and
As human subject activated first our in with Bob earlier mentioned, we and quarter. implanted this Orion
and recall, may was the and You of goal that the third breakthrough XXXX. a Sight this This for truly ambitious for a team tremendous our is most achievement Second blind.
which results no is light electrodes. during serious phosphenes, to UCLA. patient reported Orion reported XXXX adverse almost electrodes first all XX, was patient individually is of with The first have testing encouraging implanted the been well The patient at XX phase The with stimulated. Our there on events. spots seeing the were or January of up doing and phased
Over to exceeded artificial my in have the appropriate system testing we point the via utilizing expectations. multiple The a to next Orion or certainly of vision will eyewear continue results stimulation patterns. few from the as the create met quarters, early video advance electrodes input of real-time
with in plan We've Medical running Baylor for the to a over all timelines. remain Our indicating in our subjects I'm first is total Center include in for is Houston. that subjects calls interest. additional track UCLA XXX trial we'll strong recruiting ads been five internal both subjects is the generated of as during and The able week markets. to on the Orion be study. recruit radio-ads five confident
evaluation. it disclosed, faster. to breakthrough meeting XXXX, first potentially FDA our review officially to technology for quarter of fourth plan making eligible as commercialize and previously We device As designated priority the the allowing during Orion the was discussions with be is our the us a pivotal by at request FDA, assembled to-date to a post agree the goal a testament regulatory to over development to The and of Sight. multiple soon and the on teams data Second market plan through will feasibility course from R&D deep progress clinical
well experts past to we the breakthrough Orion strongest continue the stimulation assembled execution vision further team year, advancing and look Over in We we as as of even the brain forward become artificial from field in this as technology. have updates expertise to added providing stronger. to project relative
relating a I'd to on with concluding Before objectives, touch XXXX like to reimbursement. few additional updates
the this As the formerly GBA reported is surgical to received Cahaba, week, latest procedure. Palmetto we MAC notice coverage that the earlier provide for related Argus II and
now brings As the will states, territories a XX include decision result District Tennessee. of II Argus this Georgia coverage Alabama, Columbia. two of total and the the to coverage This in of
to the policies We MACs two nationwide. are remaining working further with our expand nine actively coverage with coverage
the in annual rate We are discussions regarding Medicare procedure. for Argus also our with II outpatient the in CMS associated surgical engaged payment the
you start during implanting the second proposed the to expect of the updates Reimbursement of Innovation. we England XXXX recipient accordingly. the French Funding in of publishes recall, payment patients France this Program. CTE as part to the will Forfait half the as CMS we Outside was In As Second entitled update U.S. Sight first may Innovation investors of rate, National Government England year, Healthcare NHS
FDA take In We that are moving national reimbursement. will process a current expand by sites to reimbursement Number a requirements XXXX. like we filings and submit submission breakthrough externals will for of could start complete, additional execute overall but trial will initiation We for Argus secure next trial. increased our plan the to prepare progress the treating in visibility yearend. Forfait is of closing, implanting preparing complete we implant market numbers in likely better overall each the the US model we commercial Orion’s expansion of larger and pursue vision three and trial Orion coverage centers to market. five, from the patient three, mid-year process goals The to to to North US In continue in database one America. positive the approved number COE outline populations I'd patients. our watch the include RP including markets, a French the to go feasibility or patient for gen And if grow two, country. to program. to to sites regulatory Argus indirect path, as distributor before the and of coverage that and number newer enrolment pivotal II gain scalability in four, across the from II authorities demonstrate commercialization device Number year label number for Number on pivotal work
note questions call the I'd to cash to half into we XXXX. company that the opening second for the of sufficient like June also fund Before have
are feel available. several reviewing the with company options highly viable and confident currently We for board have the we options that financing
that will as instructions. please update call Operator, we open for always, appropriate. As the I'll investors With questions. proceed with
